Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | November 8, 2010 | ||||
Last Updated Date | November 8, 2010 | ||||
Start Date ICMJE | November 2011 | ||||
Estimated Primary Completion Date | November 2013 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Clinical Pregnancy [ Time Frame: 4 weeks after insemintation ] [ Designated as safety issue: No ] A pregnancy test will be performed 2 weeks after insemination (Serum hCG) an intrauterine pregnancy will be confirmed using a transvaginal ultrasound 2 weeks after a positive pregnancy test |
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | No Changes Posted | ||||
Current Secondary Outcome Measures ICMJE | |||||
Original Secondary Outcome Measures ICMJE | |||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Luteal Phase Support With Progesterone Versus Estrogen and Progesterone on Pregnancy Rates | ||||
Official Title ICMJE | Luteal Phase Support With Progesterone vs Estrogen and Progesterone on Pregnancy Rates in Ovarian Stimulation and Intrauterine Insemination Cycles: a Prospective Randomized Study | ||||
Brief Summary | This is a single center, 3 arms, prospective randomized controlled open study to determine the impact of luteal phase support on pregnancy rates in ovarian stimulation and IUI cycles with recombinant FSH in patients with unexplained infertility and mild male factor. Patients will be randomized into 3 groups:
|
||||
Detailed Description | Study design: single center, 3 arms, prospective randomized controlled open study Objective: to determine the impact of luteal phase support on pregnancy rates in ovarian stimulation and IUI cycles with recombinant FSH in patients with unexplained infertility and mild male factor. Methods: All patients in all study groups will undergo a single insemination procedure and then will be randomized into 3 groups:
Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived. A pregnancy test will be performed 2 weeks after insemination (Serum hCG) an intrauterine pregnancy will be confirmed using a transvaginal ultrasound 2 weeks after a positive pregnancy test. If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group. |
||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 4 | ||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
||||
Condition ICMJE |
|
||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Not yet recruiting | ||||
Estimated Enrollment ICMJE | 400 | ||||
Estimated Completion Date | November 2013 | ||||
Estimated Primary Completion Date | November 2013 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Both | ||||
Ages | 20 Years to 40 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE |
|
||||
Location Countries ICMJE | Israel | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT01237535 | ||||
Other Study ID Numbers ICMJE | rmc005788ctil | ||||
Has Data Monitoring Committee | No | ||||
Responsible Party | Dr. Galia Oron, Rabin medical center | ||||
Study Sponsor ICMJE | Rabin Medical Center | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Rabin Medical Center | ||||
Verification Date | November 2010 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |